EIM
BOLD

Essex Investment Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Essex Investment Management’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-44,228
Closed -$1.75M – 561
2018
Q3 		$1.75M Hold
44,228
– – 0.21% 153
2018
Q2 		$1.69M Sell
44,228
-13,449
-23% -$498K 0.21% 150
2018
Q1 		$1.73M Sell
57,677
-11,988
-17% -$406K 0.23% 130
2017
Q4 		$2.18M Buy
69,665
+52,184
+299% +$1.43M 0.29% 107
2017
Q3 		$490K Buy
+17,481
New +$380K 0.07% 265

Other funds holding BOLD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

Essex Investment Management's BOLD Position: Q4 2018 in Review

Essex Investment Management sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2018, closing a stake of 44,228 shares — an estimated $1.75M sold.

Essex Investment Management first reported a position in BOLD in Q3 2017 and held it in 5 quarters. The position peaked at $2.18M in Q4 2017. 126 funds tracked by Wall St. Rank hold BOLD as of Q4 2018.

  • Essex Investment Management reported no remaining Audentes Therapeutics, Inc position as of Q4 2018 after selling out during the quarter.
  • Essex Investment Management sold 44,228 Audentes Therapeutics, Inc shares in Q4 2018, an estimated $1.75M.
  • Essex Investment Management first reported a position in Audentes Therapeutics, Inc in Q3 2017 and held it in 5 quarters.
  • Essex Investment Management's Audentes Therapeutics, Inc position peaked at $2.18M in Q4 2017.
  • 126 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2018.

Based on Essex Investment Management's 13F filing for Q4 2018, filed 6 Feb 2019.